Recombinant Cynomolgus Monkey TNFSF14 Protein, His (Fc)-Avi-tagged

• Cat.No.: TNFSF14-783C
• Product Overview: Recombinant Cynomolgus Monkey TNFSF14 with His (Fc)-Avi tag was expressed and purified

Specification

• Source: HEK293
• Species: Cynomolgus Monkey
• Tag: His&Fc&Avi
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: ≥85% by SDS-PAGE
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Macaca fascicularis (crab-eating macaque) ]
• Official Symbol: TNFSF14
• Synonyms: TNFSF14; tumor necrosis factor ligand superfamily member 14
• Gene ID: 102130835
• mRNA Refseq: NM_001287647
• Protein Refseq: NP_001274576
• UniProt ID: E9NVF7

Reviews

07/28/2020

The extended longevity of results gave us the confidence to delve deeper into complex biological processes.

08/01/2018

It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.

06/19/2016

The ability to obtain enduring results positively influenced the depth of our investigations.

Q&As

What are the primary changes induced by TNFSF14 in the tumor microenvironment?

TNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.

What challenges remain in utilizing TNFSF14 for cancer immunotherapy?

While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.

What does TNFSF14 stand for?

TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.

How can TNFSF14 synergize with other immunotherapy modalities?

TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.

In what context has TNFSF14 been utilized to combat cancer?

TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.

How long has TNFSF14 been in pre-clinical development?

TNFSF14 has been in pre-clinical development for over a decade.

What is the primary promise of TNFSF14 in the field of cancer immunotherapy?

TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.